Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206776 · ClinicalTrials.gov registry record · Phase 2
Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02206776 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 2 participants.
The verdict
NCT02206776, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3 months), and even then they usually only partially reduce OCD symptoms. The present study, will test if intranasal ketamine is feasible to use and can reduce OCD symptoms significantly more than a comparison medication called midazolam. Therefore, you may or may not receive ketamine as part of this study. Results from this study will allow doctors and researchers to better understand if you and others with OCD may respond to this class of medications.
Interventions
- DRUG Intranasal Midazolam
- DRUG Intranasal Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206776
The ClinicalTrials.gov registry entry for NCT02206776 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intranasal Midazolam is the first listed.
NCT02206776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02206776 about?
NCT02206776 is a clinical study titled "Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD". Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3 months), and even then they usua...
What is the current status of trial NCT02206776?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2014-09. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02206776?
The interventions under investigation include: Intranasal Midazolam (DRUG), Intranasal Ketamine (DRUG).
Who is sponsoring clinical trial NCT02206776?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.